IMCI is well-positioned to lead the next evolution of cannabis medication with its patented and effective cannabinoid-based treatments to treat chronic indications.

Aiming at large and fast-growing markets with a potential of 20% CAGR, and an estimated value of US$70 Bn by 2030 (in Israel, Europe, and the USA).

​

​

Join us and be part of this exciting new development.